Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

被引：1

作者：

Pan, Jonathan ^{[1
]}

Ghimire, Sushil ^{[1
]}

Alpdogan, S. Onder ^{[1
]}

Chapman, Andrew ^{[1
]}

Carabasi, Matthew ^{[1
]}

DiMeglio, Martina ^{[1
]}

Gong, Jerald ^{[2
]}

Martinez-Outschoorn, Ubaldo ^{[1
]}

Rose, Lewis ^{[1
]}

Ramirez, Michael ^{[1
]}

Wagner, John L. ^{[1
]}

Weiss, Mark ^{[1
]}

Flomenberg, Neal ^{[1
]}

Pro, Barbara ^{[1
,3
]}

Porcu, Pierluigi ^{[1
]}

Filicko-OHara, Joanne ^{[1
]}

Gaballa, Sameh ^{[1
,4
]}

机构：

[1] Thomas Jefferson Univ Hosp, Dept Med Oncol, Philadelphia, PA USA

[2] Thomas Jefferson Univ Hosp, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA

[3] Northwestern Univ, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, 12902 Magnolia Dr, Tampa, FL 33612 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 03期

关键词：

Relapsed; Refractory NHL; bendamustine; ofatumumab; AUTOLOGOUS TRANSPLANTATION; 1ST-LINE TREATMENT; RITUXIMAB; MULTICENTER; CHEMOTHERAPY; INDOLENT; BLOOD; TRIAL; ICE;

D O I：

10.1080/10428194.2020.1842400

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We developed an outpatient salvage chemotherapy regimen using bendamustine, ofatumumab, carboplatin and etoposide (BOCE) to treat relapsed/refractory non-Hodgkin lymphoma (RR NHL) in a single-center phase I/II study. Primary objectives were safety, tolerability and overall response rate (ORR). Thirty-five RR NHL patients (57% de novo large cell [DLBCL] or grade 3B follicular [FL], 26% transformed DLBCL, 9% grade 3A FL, 3% mantle cell; median age = 62, median prior therapies = 1) were treated. Median follow-up was 24.1 months. ORR was 69% (CR = 49%, PR = 20% [ORR = 70%, CR = 50%, PR = 20% in the de novo DLBCL/grade 3B FL subgroup]). Median progression-free survival was 5.1 months and overall-survival 26.2 months. Twelve patients subsequently underwent stem cell transplantation. The most common non-hematologic grade 3-4 toxicities were neutropenic fever and hypophosphatemia. There were no treatment-related deaths. In conclusion, BOCE is a safe and effective outpatient salvage regimen for patients with RR NHL and serves as an effective bridge to stem cell transplantation.

引用

页码：590 / 597

页数：8

共 25 条

[1] Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma [J].

Barth, Matthew J. ;

Hernandez-Ilizaliturri, Francisco J. ;

Mavis, Cory ;

Tsai, Ping-Chiao ;

Gibbs, John F. ;

Deeb, George ;

Czuczman, Myron S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (04) :490-498

[2] Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy [J].

Bologna, Luca ;

Gotti, Elisa ;

Da Roit, Fabio ;

Intermesoli, Tamara ;

Rambaldi, Alessandro ;

Introna, Martino ;

Golay, Josee .

JOURNAL OF IMMUNOLOGY, 2013, 190 (01) :231-239

[3] Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial [J].

Budde, Lihua E. ;

Wu, David ;

Martin, Daniel B. ;

Philip, Mary ;

Shustov, Andrei R. ;

Smith, Stephen D. ;

Gooley, Ted A. ;

Chen, Tara L. ;

Libby, Edward N. ;

Chen, Eric Y. ;

Kojouri, Kiarash ;

Langerak, Alan ;

Roden, Jennifer E. ;

Press, Oliver W. ;

Gopal, Ajay K. .

BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (04) :601-607

[4] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[5] A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma [J].

Coiffier, Bertrand ;

Radford, John ;

Bosly, Andre ;

Martinelli, Giovanni ;

Barca, Gabriela ;

Davies, Andrew ;

Decaudin, Didier ;

Gallop-Evans, Eve ;

Padmanabhan-Iyer, Swaminathan ;

Van Eygen, Koen ;

Wu, Ka Lung ;

Gupta, Ira V. ;

Lin, Thomas S. ;

Goldstein, Nancy ;

Jewell, Roxanne C. ;

Winter, Paul ;

Lisby, Steen .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (03) :334-342

[6]

Crump M, 2014, J CLIN ONCOL, V32

[7] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[8] Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study [J].

Flinn, Ian W. ;

van der Jagt, Richard ;

Kahl, Brad S. ;

Wood, Peter ;

Hawkins, Tim E. ;

MacDonald, David ;

Hertzberg, Mark ;

Kwan, Yiu-Lam ;

Simpson, David ;

Craig, Michael ;

Kolibaba, Kathryn ;

Issa, Samar ;

Clementi, Regina ;

Hallman, Doreen M. ;

Munteanu, Mihaela ;

Chen, Ling ;

Burke, John M. .

BLOOD, 2014, 123 (19) :2944-2952

[9] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[10] Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma [J].

Green, D. J. ;

Bensinger, W. I. ;

Holmberg, L. A. ;

Gooley, T. ;

Till, B. G. ;

Budde, L. E. ;

Pagel, J. M. ;

Frayo, S. L. ;

Roden, J. E. ;

Hedin, L. ;

Press, O. W. ;

Gopal, A. K. .

BONE MARROW TRANSPLANTATION, 2016, 51 (10) :1330-1336

← 1 2 3 →